COMPARATIVE STUDY OF HORMONAL AND NON HORMONAL TREATMENTS FOR THE MANAGEMENT OF MENOPAUSAL SYMPTOMS

  • Sujata Singh
  • D C Dhasmana Himalayan Institute of Medical Sciences, Jolly Grant, Dehradun -248140, U.K., India
  • Shaktibala Dutta Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun -248001, U.K., India
  • Vineeta Gupta Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun -248001, U.K., India

Abstract

Objective : This study was conducted with the objective of comparing safety and efficacy of hormonal treatment and non hormonal alternatives for the management of menopausal symptoms.

Materials and Methods: A total of 40 patients suffering from menopausal symptoms were recruited to the study protocol and were divided into 4 groups according to the treatment they received, with 10 patients in each group. Group A received conjugated estrogen and medroxy progesterone acetate, Group B received Tibolone, Group C received Isoflavone and Group D received Vitamin E. Efficacy of the treatment was evaluated by improvement in symptomatic score and safety of the treatment was assessed on the basis of adverse effects reported and relevant laboratory investigations.

Results: Most of the symptoms were significantly improved in groups A and B (p< 0.01) while in groups C and D significant improvement was observed in hot flushes, sweating and insomnia (p<0.05). On comparative analysis there was no significant difference in the efficacy between groups A and B and between groups C and D. On the other hand significant difference was observed in the efficacy when groups A and B were compared with groups C and D (p<0.01). Only mild tolerable side effects were reported by the patients in all the groups with slightly higher incidence in groups A and B.

Conclusions : Hormonal treatment is very efficacious for the early relief of menopausal symptoms. Isoflavone and vitamin E can be considered as a satisfactory treatment alternative when for any reasons hormonal treatment cannot be used.

KEY WORDS:  HRT, Tibolone , Isoflavone, Menopausal symptoms

Keywords: Therapeutics

Downloads

Download data is not yet available.

Author Biographies

Sujata Singh

Associate Professor, Deptt of

Pharmacology,SRMSIMS, Bareilly

 

D C Dhasmana, Himalayan Institute of Medical Sciences, Jolly Grant, Dehradun -248140, U.K., India

Himalayan Institute of Medical Sciences, Jolly Grant, Dehradun -248140, U.K., India

Shaktibala Dutta, Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun -248001, U.K., India

Shri Guru Ram Rai Institute of Medical & Health  Sciences, Dehradun -248001, U.K., India

Vineeta Gupta, Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun -248001, U.K., India

Shri Guru Ram Rai Institute of Medical & Health  Sciences, Dehradun -248001, U.K., India

References

1. Vaze N, Joshi S. Yoga and menopausal transition. J Midlife Health 2010; 1:56-8.
------
2. Mishra N, Mishra VN, Devanshi. Exercise beyond menopause: Dos and don'ts. J Midlife Health 2011;2:51-6.
------
3. Miller RG, Ashar BH. Managing menopause: current therapeutic options for vasomotor symptoms. Adv Stud Med 2004; 4: 484-92.
------
4. Hulley S, Furberg C, Barrett-Connor E. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement study follow-up (HERS II). JAMA 2002; 288:58-66.
------
5. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
------
6. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012;15(3):217– 28.
------
7. Panay N, Hamoda H, Arya R, Savvas M. The 2013 British Menopause Society and Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int. 2013;19(2):59–68.
------
8. Egarter CH, Huber J, Leikermoser R, Haidbauer R, Pusch H, Fischl F, Putz M. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996; 23:55-62.
------
9. Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas. 2005;50:222-230 .
------
10. Hammer M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind randomized trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br. J Obstet Gynaecol 1998; 105:904-911.
------
11. Davis SR. The effects of tibolone on mood and libido. Menopause 2002; 9:162-170.
------
12. Thomas B. Clarkson, Ellen B Gold, Shehzad S. Basaria, Takeshi Aso, Fredi Kronenberg, Cara L. Frankenfeld.The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011; 18( 7): 732-53
------
13. Han KK, Soares JM, Haidar MA. Benefits of Soy Isoflavone Therapeutic Regimen on Menopausal Symptoms. Obstet Gynecol 2002; 99: 389–94.
------
14. Sirtori CR. Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. Drug Saf 2001; 24: 665–82.
------
15. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16: 495-500.
------
16. Loprinzi CL, Barton Dl, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet 2001; 2:199-204
------
17. Deka D. Role of micronutrients in the management of menopause. In: Purandare CN, Khadikar SS, editors. Menopause Current Concepts, 1st edition, New Delhi: Jaypee Brothers Medical Publishers (P) Ltd,; 2004: p. 66–71.
------
Statistics
82 Views | 70 Downloads
How to Cite
Singh, S., Dhasmana, D., Dutta, S., & Gupta, V. (2015). COMPARATIVE STUDY OF HORMONAL AND NON HORMONAL TREATMENTS FOR THE MANAGEMENT OF MENOPAUSAL SYMPTOMS. Journal of Drug Delivery and Therapeutics, 5(1), 82-87. https://doi.org/10.22270/jddt.v5i1.1055